BIOMARKER:

FGFR3-TACC3 fusion

Entrez ID:

Related biomarkers:

‹

›

FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	Debio 1347 Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Glioblastoma GBM	erdafitinib Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Non Small Cell Lung Cancer NSCLC	infigratinib Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Non Small Cell Lung Cancer NSCLC	ponatinib Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Glioma Glioma	anlotinib Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Glioblastoma GBM	anlotinib Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Endometrial Cancer Endometrial Cancer	erdafitinib Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Bladder Cancer Bladder Cancer	erdafitinib Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	atezolizumab Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	erdafitinib Sensitive: D – Preclinical
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Bladder Cancer Bladder Cancer	MPT0L145 Sensitive: D – Preclinical
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: D – Preclinical
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	dasatinib + infigratinib Sensitive: D – Preclinical